Please assess the completion status of the following clinical trial:

Trial Title: Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Spinal Cord Injured~* Between the ages of 18-65 years old.~* Level of injury is between C1-T12~* Primarily wheelchair dependent for ambulation~* Have a spinal cord injury that is ASIA Impairment Scale (AIS) grade of A, B or C~* Injury occurred more than 1 year ago~* Low blood pressure (Systolic BP less than 110 mmHg for males, Systolic BP less than 100 mmHg for females)~* Primary language is English~* I am right handed~Exclusion Criteria:~* Currently have an illness or infection~* Severe history of AD (more than 3 symptomatic events per week, evidence of blood pressure elevations above 140/90 mmHg,significant adverse subjective symptoms reporting)~* Hypertension or diabetes~* History of Traumatic Brain Injury (TBI)~* Neurological condition other than SCI (Alzheimer's disease, dementia, stroke, multiple sclerosis, Parkinson's disease, etc.)~* History of epilepsy or other seizure disorder~* Diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder~* Within the past 6 months, abused illicit drugs~* Pre-screen mini mental status exam score of less than 24, as rated by the researcher~* Vision is impaired- more than 20/60 in worst eye (with prescription eyewear)~* Coronary heart and/or artery disease~* Major surgery in the last 30 days~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Midodrine (Type: EXPERIMENTAL): Arm 1 last 30 days. Subject will either be given midodrine or placebo to take during Arm 1.
- Placebo (Type: PLACEBO_COMPARATOR): Arm 2 is followed by a 14 day washout period. Arm 2 last 30 days. Subject will be given a drug (placebo or midodrine) to take during Arm 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).